RecruitingRecruiting
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
NCT07807345 · Sutro Biopharma, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 1 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO 006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
About this study
This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts:
* Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6. Part 1A will determine the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of STRO-006.
* Part 1B is a dose expansion in one or more indications, as determined by the Sponsor, to further evaluate a STRO-006 monotherapy dose, examine anti-tumor activity, and determine the recommended Phase 2 dose (RP2D) of STRO-006 monotherapy.
* Part 1C is a combination dose escalation to determine safety, tolerability, PK, and preliminary anti-tumor activity of STRO-006 combined with pembrolizumab.
Eligibility criteria
Inclusion Criteria:
* Histologically or cytologically documented refractory solid tumors that are recurrent or metastatic including: HNSCC (excluding EBV-positive nasopharyngeal carcinoma), NSCLC, esophageal/gastric cancer, colorectal cancer, endometrial carcinoma, urothelial carcinoma, and breast cancer (HR-positive \[HER2-positive or HER2-negative\] and TNBC subtype)
* Age ≥ 18 years
* Life expectancy of at least 3 months
* Willingness and ability to comply with the study protocol and long
* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1-term follow-up (LTFU) assessments
* Has received standard systemic therapies with known clinical benefit, or is considered inappropriate for such therapies, in the opinion of the investigator. In the dose escalation Phases (Parts 1A and 1C), there is no limit on the number of prior therapies
* Expansion Phase (Part 1B) only: Up to two prior therapies are allowed. For participants with AGA-driven adenocarcinoma NSCLC up to four prior therapies are allowed
* Measurable disease per RECIST v1.1.
* Adequate hematologic and organ function
Exclusion Criteria:
* Prior anticancer treatment with an ADC with a TOP1 inhibitor payload. (Prior therapy with an ITGB6-targeted ADC is otherwise allowed.)
* Prior anticancer therapy (prior to first dose of study treatment): chemotherapy within ≤ 2 weeks, ICI ≤ 3 weeks, ADCs ≤ 3 weeks, palliative radiation therapy ≤ 2 weeks, and major surgery ≤ 4 weeks of C1D1. If not specified, ≥ 5 half-lives or 2 weeks, whichever is longer, since administration of prior therapy must have elapsed
* Residual Common Terminology Criteria for Adverse Events (CTCAE) v5 ≥ Grade 2 toxicity from prior anticancer therapy, with the exception of Grade 2 alopecia or Grade 2 peripheral neuropathy, which is controlled, and endocrinopathies secondary to prior ICI controlled by hormonal treatment. For Part 1C only: discontinued prior immunotherapy due to treatment-related toxicity
* Untreated or active brain metastases and/or leptomeningeal disease
* Participants with active ILD or active, non-infectious pneumonitis or a history of active pneumonitis ≤ 6 months from the first dose of study treatment
* Significant, concurrent renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral, or psychiatric disease that could impact participation in this clinical trial
* Previous solid organ or bone marrow transplantation
* Concurrent participation in another therapeutic treatment trial
Study design
Enrollment target: 285 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-10-19
Estimated completion: 2028-12
Last updated: 2026-10-23
Interventions
Drug: STRO-006Drug: Pembrolizumab
Primary outcomes
- • Part 1A, 1C: Incidence and severity of Dost-limiting Toxicities (DLTs) (21 days)
- • Part 1A, 1C: Incidence and severity of Treatment-Emergent Adverse Events (TEAEs) (21 days)
- • Part 1B: Objective Response Rate (ORR) (2.5 years)
Sponsor
Sutro Biopharma, Inc. · industry
Contacts & investigators
ContactSutro Clinical Team · contact · clinicaltrials@sutrobio.com · 650-801-6416
InvestigatorJennifer Oliver · study_director, Sutro Biopharma
All locations (6)
SCRI at Florida Cancer SpecialistsRecruiting
Orlando, Florida, United States
Massachusetts General BrighamNot Yet Recruiting
Boston, Massachusetts, United States
OU Health Stephenson Cancer CenterNot Yet Recruiting
Oklahoma City, Oklahoma, United States
NEXT Oncology DallasRecruiting
Irving, Texas, United States
Texas Tech University Health Sciences CenterNot Yet Recruiting
Lubbock, Texas, United States
NEXT Oncology VirginiaRecruiting
Fairfax, Virginia, United States